Inhibiting the TGF-beta signalling pathway as a means of cancer immunotherapy (Q35093612)

6 August 2017

1 reference

title

Inhibiting the TGF-beta signalling pathway as a means of cancer immunotherapy (English)

1 reference

6 August 2017

1 reference

Gerard C Blobe

1 reference

6 August 2017

Kellye C Kirkbride

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 April 2003

1 reference

Expert Opinion on Biological Therapy

6 August 2017

published in

1 reference

6 August 2017

1 reference

6 August 2017

1 reference

6 August 2017

page(s)

251-261

1 reference

Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B.

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.251

Purification and initial characterization of a type beta transforming growth factor from human placenta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.251

The host-tumor immune conflict: from immunosuppression to resistance and destruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.251

Role of TGF-beta in immune-evasion of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.251

TGF-beta-based immunotherapy for cancer: breaching the tumor firewall

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.251

Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.251

Transforming growth factor beta1 (TGF-beta1) is a preoperative prognostic indicator in advanced gastric carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.251

The prognostic significance of transforming growth factors in human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.251

The expression of transforming growth factor-beta1 is significantly correlated with the expression of vascular endothelial growth factor and poor prognosis of patients with advanced gastric carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.251

Divergence and convergence of TGF-beta/BMP signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.251

The transforming growth factor-beta family

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.251

Disruption of the gene encoding the latent transforming growth factor-beta binding protein 4 (LTBP-4) causes abnormal lung development, cardiomyopathy, and colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.251

Abnormal lung development and cleft palate in mice lacking TGF-beta 3 indicates defects of epithelial-mesenchymal interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.251

Targeted mutations of transforming growth factor-beta genes reveal important roles in mouse development and adult homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.251

TGF-beta signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.251

Functional roles for the cytoplasmic domain of the type III transforming growth factor beta receptor in regulating transforming growth factor beta signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.251

Requirement of type III TGF-beta receptor for endocardial cell transformation in the heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.251

Betaglycan binds inhibin and can mediate functional antagonism of activin signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.251

TGF-beta receptor-activated p38 MAP kinase mediates Smad-independent TGF-beta responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.251

Abnormal angiogenesis but intact hematopoietic potential in TGF-beta type I receptor-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.251

Role of transforming growth factor beta in human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.251

Transforming growth factor-beta: vasculogenesis, angiogenesis, and vessel wall integrity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.251

TGF-beta receptor type II deficiency results in defects of yolk sac hematopoiesis and vasculogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.251

Disruption of the antiproliferative TGF-beta signaling pathways in human pancreatic cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.251

Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.251

Regulation of immune responses by TGF-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.251

Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.251

Transforming growth factor-beta in T-cell biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.251

Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.251

Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.251

Blockade of transforming growth factor beta/Smad signaling in T cells by overexpression of Smad7 enhances antigen-induced airway inflammation and airway reactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.251

Disruption of T cell homeostasis in mice expressing a T cell-specific dominant negative transforming growth factor beta II receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.251

Incidence of apoptosis and cell proliferation in prostate cancer: relationship with TGF-beta1 and bcl-2 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.251

Down-regulation of TGF-beta1 production restores immunogenicity in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.251

Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.251

RNA interference: genetic wand and genetic watchdog

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.251

SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.2.251

21 January 2018

Identifiers

DOI

10.1517/14712598.3.2.251

1 reference

6 August 2017

1 reference